The Medicines Co. Takes On The Gram-Negative Competition
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Hospital-focused specialty firm expects novel beta lactamase inhibitor in Carbavance will provide a crucial advantage in attacking developing gram-negative infections. TMC also is re-launching tetracycline antibiotic Minocin for gram-negative infections, while developing a follow-on formulation that should offer easier administration.